Emergent BioSolutions (EBS) Cash from Operations (2010 - 2026)

Emergent BioSolutions' Cash from Operations history runs 17 years deep, the most recent figure standing at 33800000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations fell 201.79% year-over-year to 33800000.0 in Q1 2026; TTM through Mar 2026 was 148000000.0, a 34.42% increase from a year earlier, with the FY2025 full-year figure at 170600000.0, up 190.63% from the prior year.
• Cash from Operations slipped to 33800000.0 in Q1 2026 per EBS's latest filing, from 77700000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 153700000.0 in Q3 2024 and bottomed at 184000000.0 in Q1 2023.
• The 5-year median for Cash from Operations is 11200000.0 (2025), against an average of 2641176.47.
• Across the five-year window, Cash from Operations tumbled 831.37% in 2022 and surged 197.25% in 2025, its largest moves.
• Year by year, Cash from Operations stood at 92800000.0 in 2022, then slumped by 65.41% to 32100000.0 in 2023, then plunged by 348.91% to 79900000.0 in 2024, then jumped by 197.25% to 77700000.0 in 2025, then sank by 143.5% to 33800000.0 in 2026.
• Per Business Quant, the three latest EBS Cash from Operations figures stand at 33800000.0 (Q1 2026), 77700000.0 (Q4 2025), and 2300000.0 (Q3 2025).